Published in Trop Med Int Health on February 01, 2010
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One (2012) 0.97
Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in ethiopian patients. PLoS One (2014) 0.83
Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. Antimicrob Agents Chemother (2015) 0.81
Elevated alanine aminotransferase in antiretroviral-naïve HIV-infected African patients: magnitude and risk factors. HIV Med (2012) 0.76
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis (2012) 3.86
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol (2007) 2.93
Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS (2002) 2.83
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med (2015) 2.48
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis (2006) 2.47
Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis (2008) 2.29
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health (2010) 1.96
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis (2011) 1.85
Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect (2009) 1.80
Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS (2002) 1.79
The tempo and mode of molecular evolution of Mycobacterium tuberculosis at patient-to-patient scale. Infect Genet Evol (2009) 1.76
Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol (2011) 1.67
Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg Infect Dis (2012) 1.65
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerg Infect Dis (2012) 1.57
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr (2003) 1.57
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS (2008) 1.55
High-resolution typing by integration of genome sequencing data in a large tuberculosis cluster. J Clin Microbiol (2010) 1.52
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis (2011) 1.52
Invasive disease caused by nontuberculous mycobacteria, Tanzania. Emerg Infect Dis (2009) 1.51
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumatol (2008) 1.50
Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg (2005) 1.46
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. Tuberculosis (Edinb) (2014) 1.43
Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother (2009) 1.36
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother (2007) 1.34
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit (2003) 1.28
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat (2012) 1.24
Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol (2010) 1.22
Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J Clin Microbiol (2013) 1.17
Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic species. Int J Syst Evol Microbiol (2010) 1.12
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS (2009) 1.11
Isolation of mycobacteria other than Mycobacterium avium from porcine lymph nodes. Vet Microbiol (2010) 1.08
International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother (2008) 1.07
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One (2013) 1.06
Laboratory diagnosis of pulmonary tuberculosis in TB and HIV endemic settings and the contribution of real time PCR for M. tuberculosis in bronchoalveolar lavage fluid. Trop Med Int Health (2007) 1.05
SNP/RD typing of Mycobacterium tuberculosis Beijing strains reveals local and worldwide disseminated clonal complexes. PLoS One (2011) 1.03
Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993-2007. Emerg Infect Dis (2011) 1.01
Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther (2011) 1.01
Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients. Antimicrob Agents Chemother (2013) 1.01
In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother (2012) 1.01
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2013) 1.00
Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ (2011) 1.00
Mutations in the regulatory network underlie the recent clonal expansion of a dominant subclone of the Mycobacterium tuberculosis Beijing genotype. Infect Genet Evol (2011) 0.99
Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med (2013) 0.99
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One (2010) 0.99
Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 0.98
Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. Ther Drug Monit (2002) 0.97
Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents (2010) 0.97
Childhood tuberculosis in the Kilimanjaro region: lessons from and for the TB programme. Trop Med Int Health (2010) 0.97
The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania. AIDS (2007) 0.96
Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr (2002) 0.95
Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health (2012) 0.95
Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents (2011) 0.95
Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther (2013) 0.93
Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis (2008) 0.93
Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. BMC Public Health (2011) 0.93
Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity. J Clin Microbiol (2013) 0.93
The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health (2011) 0.91
Comparison of overnight pooled and standard sputum collection method for patients with suspected pulmonary tuberculosis in northern Tanzania. Tuberc Res Treat (2012) 0.91
Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species. Int J Syst Evol Microbiol (2009) 0.90
Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis (2013) 0.89
In vitro activity of thioridazine against mycobacteria. Int J Antimicrob Agents (2009) 0.89
Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents (2008) 0.88
Transfer of newborns to neonatal care unit: a registry based study in Northern Tanzania. BMC Pregnancy Childbirth (2011) 0.88
Preferential deletion events in the direct repeat locus of Mycobacterium tuberculosis. J Clin Microbiol (2011) 0.88
Prevalence and risk factors for infection of bovine tuberculosis in indigenous cattle in the Serengeti ecosystem, Tanzania. BMC Vet Res (2013) 0.87
Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J Antimicrob Chemother (2011) 0.87
Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis (2008) 0.87
Clinical relevance of nontuberculous Mycobacteria, Oman. Emerg Infect Dis (2009) 0.86
Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients. Int J Syst Evol Microbiol (2009) 0.86
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr (2003) 0.84
Pros and cons of therapeutic drug monitoring of antiretroviral agents. Curr Opin Infect Dis (2002) 0.84
Upper gastrointestinal endoscopic findings and prevalence of Helicobacter pylori infection among adult patients with dyspepsia in northern Tanzania. Tanzan J Health Res (2014) 0.82